Verition Fund Management
CYCN icon

Verition Fund Management’s Cyclerion Therapeutics CYCN Stock Holding History

Verition Fund Management’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,000
Closed -$17K – 2266
2022
Q3 		$17K Hold
1,000
– – ﹤0.01% 2810
2022
Q2 		$11K Hold
1,000
– – ﹤0.01% 2250
2022
Q1 		$22K Hold
1,000
– – ﹤0.01% 2593
2021
Q4 		$34K Hold
1,000
– – ﹤0.01% 2452
2021
Q3 		$61K Hold
1,000
– – ﹤0.01% 1760
2021
Q2 		$78K Hold
1,000
– – ﹤0.01% 1765
2021
Q1 		$56K Hold
1,000
– – ﹤0.01% 1469
2020
Q4 		$61K Hold
1,000
– – ﹤0.01% 1035
2020
Q3 		$122K Buy
1,000
+250
+33% +$28.6K ﹤0.01% 982
2020
Q2 		$89K Hold
750
– – ﹤0.01% 1005
2020
Q1 		$40K Buy
+750
New +$53.5K ﹤0.01% 546

Other funds holding CYCN

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TFS
TrustCore Financial Services Brentwood, Tennessee $1.14B AUM 13.32% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Verition Fund Management's CYCN Position: Q4 2022 in Review

Verition Fund Management sold out of Cyclerion Therapeutics (CYCN) in Q4 2022, closing a stake of 1,000 shares — an estimated $17K sold.

Verition Fund Management first reported a position in CYCN in Q1 2020 and held it in 11 quarters. The position peaked at $122K in Q3 2020. 40 funds tracked by Wall St. Rank hold CYCN as of Q4 2022.

  • Verition Fund Management reported no remaining Cyclerion Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Verition Fund Management sold 1,000 Cyclerion Therapeutics shares in Q4 2022, an estimated $17K.
  • Verition Fund Management first reported a position in Cyclerion Therapeutics in Q1 2020 and held it in 11 quarters.
  • Verition Fund Management's Cyclerion Therapeutics position peaked at $122K in Q3 2020.
  • 40 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q4 2022.

Based on Verition Fund Management's 13F filing for Q4 2022, filed 14 Feb 2023.